Ipsen completes acquisition of Kartos Therapeutics
August 21, 2026
Ipsen has completed its acquisition of Kartos Therapeutics, adding the late-stage MDM2 inhibitor navtemadlin to its oncology pipeline. Navtemadlin is in Phase III development for myelofibrosis as an add-on therapy to ruxolitinib for patients with a suboptimal response to standard treatment.
- Buyers
- Ipsen
- Targets
- Kartos Therapeutics
- Industry
- Pharmaceuticals
- Location
- United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.